2022/07/16 by Wei Xu, Zhiqiang Wang, Zhi Zhang +2
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer-related gene regulation #Lung Cancer Treatments and Mutations #Pancreatic and Hepatic Oncology Research
paper · doi:10.1002/cbin.11847
openalex publication_date 2022/07/16 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/22
PIK3CB is abnormally expressed in various carcinomas and affects the proliferation, invasion and drug resistance of cancer cells. However, its role in oesophageal squamous cell carcinoma (ESCC) is still unclear. In this study, PIK3CB was found to be highly expressed in ESCC tissues and cells and positively correlated with the poor prognosis of ESCC. Silencing PIK3CB inhibited the proliferation of ESCC cells, arrested the cell cycle, and promoted apoptosis. Mechanistic studies showed that the tumour-promoting effect of PIK3CB was achieved through PI3K/AKT/mTOR signalling pathway activation. Moreover, the high PIK3CB expression level in ESCC may be closely associated with the hypomethylation status of the gene promoter. In conclusion, PIK3CB promotes ESCC by activating the PI3K/AKT/mTOR signalling axis. PIK3CB may be a potential target in ESCC.